Evaluation of the Quality of Life in Adult Cancer Survivors (QLACS) scale for long-term cancer survivors in a sample of breast cancer survivors

Evaluation of the Quality of Life in Adult Cancer Survivors (QLACS) scale for long-term cancer survivors in a sample of breast cancer survivors

Blog Article

Abstract Background This paper evaluates psychometric properties of a recently developed measure focusing on the health-related quality of life (HRQL) of long-term cancer survivors, the Quality of Life in Adult Survivors scale (QLACS), in a sample of breast cancer survivors.This represents an important area of study, given the large number of breast cancer patients surviving many years post diagnosis.Methods Analyses are based on an 8-year follow-up of a sample of breast cancer survivors who participated in an earlier study conducted in 1995.Participants were re-contacted in 2003 and those who were reachable and agreed to participate (n = 94) were surveyed using a variety of measures including the QLACS.

Additional follow-up surveys were conducted 2 weeks and one Dressing Aids year later.Psychometric tests of the QLACS included test-retest reliability, concurrent and retrospective validity, and responsiveness.Results The QLACS T-Shirt domain and summary scores showed good test-retest reliability (all test-retest correlations were above.7) and high internal consistency.

The Generic Summary Score showed convergent validity with other measures designed to assess generic HRQL.The Cancer-Specific Summary score exhibited divergent validity with generic HRQL measures, but not a cancer-related specific measure.The QLACS Cancer-Specific Summary Score demonstrated satisfactory predictive validity for factors that were previously shown to be correlated with HRQL.The QLACS generally demonstrated a high level of responsiveness to life changes.

Conclusion The QLACS may serve as a useful measure for assessing HRQL among long-term breast cancer survivors that are not otherwise captured by generic measures or those specifically designed for newly diagnosed patients.